Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original

July 2009

The recent Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original.

These "follow-on" drugs are the latest trend for drug companies looking to replace drugs with expiring patents.

But these new versions usually don't offer much improvement.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote